Evidence map›Paper›PMID 27926742›Full record

ArticleJAMA psychiatry2017

Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia.

Michael L Thomas, Michael F Green, Gerhard Hellemann, Catherine A Sugar, Melissa Tarasenko, Monica E Calkins, Tiffany A Greenwood, Raquel E Gur, Ruben C Gur, Laura C Lazzeroni and 14 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 1 synthesis or guideline pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  16. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 1 country.

Michael L ThomasDepartment of Psychiatry, University of California, San Diego, La Jolla2VISN-22 Mental Illness Research, Education, and Clinical Center, Veterans Affairs (VA) San Diego Healthcare System, San Diego, California.
Michael F GreenDepartment of Psychiatry and Biobehavioral Sciences, UCLA (University of California Los Angeles)4VISN-22 Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California.
Gerhard HellemannDepartment of Psychiatry and Biobehavioral Sciences, UCLA (University of California Los Angeles)4VISN-22 Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California.
Catherine A SugarDepartment of Biostatistics, University of California, Los Angeles, School of Public Health, Los Angeles.
Melissa TarasenkoDepartment of Psychiatry, University of California, San Diego, La Jolla2VISN-22 Mental Illness Research, Education, and Clinical Center, Veterans Affairs (VA) San Diego Healthcare System, San Diego, California.
Monica E CalkinsDepartment of Psychiatry, University of Pennsylvania, Philadelphia.
Tiffany A GreenwoodDepartment of Psychiatry, University of California, San Diego, La Jolla.
Raquel E GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia.
Ruben C GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia.
Laura C LazzeroniDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.
Keith H NuechterleinDepartment of Psychiatry and Biobehavioral Sciences, UCLA (University of California Los Angeles).
Allen D RadantDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle9VISN-20 Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington.
Larry J SeidmanDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts11Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston.
Alexandra L ShilukDepartment of Psychiatry, University of California, San Diego, La Jolla.
Larry J SieverDepartment of Psychiatry, The Mount Sinai School of Medicine, New York, New York13VISN-3 Mental Illness Research, Education, and Clinical Center, James J. Peters VA Medical Center, New York, New York.
Jeremy M SilvermanDepartment of Psychiatry, The Mount Sinai School of Medicine, New York, New York13VISN-3 Mental Illness Research, Education, and Clinical Center, James J. Peters VA Medical Center, New York, New York.
Joyce SprockDepartment of Psychiatry, University of California, San Diego, La Jolla.
William S StoneDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts11Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston.
Neal R SwerdlowDepartment of Psychiatry, University of California, San Diego, La Jolla.
Debby W TsuangDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle9VISN-20 Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington.
Ming T TsuangDepartment of Psychiatry, University of California, San Diego, La Jolla14Center for Behavioral Genomics, and Institute for Genomic Medicine, University of California, San Diego, La Jolla15Harvard Institute of Psychiatric Epidemiology and Genetics, Boston, Massachusetts16VISN-20 Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington.
Bruce I TuretskyDepartment of Psychiatry, University of Pennsylvania, Philadelphia.
David L BraffDepartment of Psychiatry, University of California, San Diego, La Jolla.
Gregory A LightDepartment of Psychiatry, University of California, San Diego, La Jolla2VISN-22 Mental Illness Research, Education, and Clinical Center, Veterans Affairs (VA) San Diego Healthcare System, San Diego, California.
University of California, San Diego · USUniversity of Pennsylvania · USHarvard University · USIcahn School of Medicine at Mount Sinai · USVA Greater Los Angeles Healthcare System · USJoint Center for Structural Genomics · USNeurobehavioral Systems · USStanford University · USUniversity of California, Los Angeles · USVA Portland Health Care System · USVA Puget Sound Health Care System · USVA San Diego Healthcare System · US

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
The Genetics of Endophenotypes and SchizophreniaR01MH065578 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 2003 to 2013
$4.2M
The Genetics of Endophenotypes and SchizophreniaR01MH065554 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SIEVER, LARRY J · 2003 to 2013
$4.1M
Genetics of Endophenotypes and SchizophreniaR01MH065558 · NIMH · UNIVERSITY OF WASHINGTON · PI TSUANG, DEBBY WEN · 2003 to 2013
$3.7M
The Genetics of Endophenotypes and SchizophreniaR01MH065707 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GREEN, MICHAEL F. · 2003 to 2013
$3.6M
Pathway(s) From Genes to Functional Deficits of Schizophrenia PatientsR01MH079777 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LIGHT, GREGORY A · 2007 to 2010
$1.4M
The Convergence and Divergence of Schizophrenia and Bipolar DisorderK01MH087889 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GREENWOOD, TIFFANY A · 2010 to 2014
$858k
Neuroimaging and Neurocognitive Computerized Adaptive Testing in SchizophreniaK23MH102420 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THOMAS, MICHAEL L · 2014 to 2018
$815k
NIMH NIH HHS K01 MH087889NIMH NIH HHS K23 MH102420NIMH NIH HHS R01 MH042228NIMH NIH HHS R01 MH065554NIMH NIH HHS R01 MH065558NIMH NIH HHS R01 MH065571NIMH NIH HHS R01 MH065578NIMH NIH HHS R01 MH065707NIMH NIH HHS R01 MH079777
6 · The paper itself

Abstract

importanceNeurophysiologic measures of early auditory information processing (EAP) are used as endophenotypes in genomic studies and biomarkers in clinical intervention studies. Research in schizophrenia has established correlations among measures of EAP, cognition, clinical symptoms, and functional outcome. Clarifying these associations by determining the pathways through which deficits in EAP affect functioning would suggest when and where to therapeutically intervene.

objectivesTo characterize the pathways from EAP to outcome and to estimate the extent to which enhancement of basic information processing might improve cognition and psychosocial functioning in schizophrenia. DESIGN, SETTING, AND

participantsCross-sectional data were analyzed using structural equation modeling to examine the associations among EAP, cognition, negative symptoms, and functional outcome. Participants were recruited from the community at 5 geographically distributed laboratories as part of the Consortium on the Genetics of Schizophrenia 2 from July 1, 2010, through January 31, 2014. This well-characterized cohort of 1415 patients with schizophrenia underwent EAP, cognitive, and thorough clinical and functional assessment. MAIN OUTCOME AND MEASURES: Mismatch negativity, P3a, and reorienting negativity were used to measure EAP. Cognition was measured by the Letter Number Span test and scales from the California Verbal Learning Test-Second Edition, the Wechsler Memory Scale-Third Edition, and the Penn Computerized Neurocognitive Battery. Negative symptoms were measured by the Scale for the Assessment of Negative Symptoms. Functional outcome was measured by the Role Functioning Scale.

resultsParticipants included 1415 unrelated outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years; 979 males [69.2%] and 619 white [43.7%]). Early auditory information processing had a direct effect on cognition (β = 0.37, P < .001), cognition had a direct effect on negative symptoms (β = -0.16, P < .001), and both cognition (β = 0.26, P < .001) and experiential negative symptoms (β = -0.75, P < .001) had direct effects on functional outcome. The indirect effect of EAP on functional outcome was significant as well (β = 0.14, P < .001). Overall, EAP had a fully mediated effect on functional outcome, engaging general rather than modality-specific cognition, with separate pathways that involved or bypassed negative symptoms. CONCLUSIONS AND RELEVANCE: The data support a model in which EAP deficits lead to poor functional outcome via impaired cognition and increased negative symptoms. Results can be used to help guide mechanistically informed, personalized treatments and support the strategy of using EAP measures as surrogate end points in early-stage procognitive intervention studies.

Indexed as

Models, PsychologicalSchizophrenic PsychologyAdultAuditory Perceptual DisordersCognition DisordersContingent Negative VariationCross-Sectional StudiesDisability EvaluationFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSocial Behavior Disorders

Identifiers

PMID27926742
PMCPMC5453308
OpenAlexW2560045063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.